Buffing Up on New and Emerging ARTA Look at the Changing HIV Playing Field
Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M).
Chounta V, Overton ET, Mills A, et al. Patient. 2021;14(6):849-862.
New York State Department of Health AIDS Institute Clinical Guidelines. In: Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults.
McGowan JP, Fine SM, et al. Baltimore, MD: Johns Hopkins University; 2021.
Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Curr Opin HIV AIDS. 2022;17(1):15-21.
Lenacapavir as part of a combination regimen in treatment-naïve PWH [people with HIV]: week 54 results.
Gupta SK, Sims J, Brinson C, et al. Presented at: Conference on Retroviruses and Opportunistic Infection. February 12-16, 2022. Abstract 138.
Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic.
Howe ZW, Norman S, Lueken AF, et al. Pharmacotherapy. 2021;41(8):686-699.
Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
Kerrigan D, Mantsios A, Gorgolas M, et al. PLoS One. 2018;13(1):e0190487.
Efficacy and freedom: patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat HIV in the context of phase 3 trials.
Mantsios A, Murray M, Karver TS, et al. AIDS Behav. 2020;24(12):3473-3481.
Ogbuagu O, Segal-Maurer S, Brinson C, et al. Presented at: Conference on Retroviruses and Opportunistic Infections; February 12-16, 2022; virtual conference. Abstract 491.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET, Richmond G, Rizzardini G, et al. Lancet. 2021;396(10267):1994-2005.
Scarsi KK, Swindells S. J Int Assoc Provid AIDS Care. 2021;20:23259582211009011.
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.
A Look at the Changing HIV Playing Field
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
The PCPs Role in Preventing HIV
Targeting Immune Dysregulation and Delivering Comprehensive Care
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Got it? Treat it!
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
The Critical Role of the Community Pharmacist
Using Imaging to Improve Patient Outcomes
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Debates & Discussions on the Evolving Role of JAK Inhibitors
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
The Evolving Role of JAK Inhibitors
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Unpacking the Evidence for Their Use Today and Tomorrow
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Unlocking Novel Paths to Patient Care
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
Preventing COPD Exacerbations to Improve Outcomes
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
From Patient Evaluations to New Targeted Therapies
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A “How To” Series Spanning Policy to Practice
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention